Ascendis Pharma A S (ASND) Analysts See $-0.78 EPS; Ascent Capital Group (ASCMA) Had 0 Bulls

August 24, 2017 - By Linda Rogers

Analysts expect Ascendis Pharma A S (NASDAQ:ASND) to report $-0.78 EPS on August, 30.They anticipate $0.18 EPS change or 30.00% from last quarter’s $-0.6 EPS. After having $-0.83 EPS previously, Ascendis Pharma A S’s analysts see -6.02% EPS growth. The stock increased 1.10% or $0.3 on August 23, reaching $27.65. About shares traded. Ascendis Pharma A S (NASDAQ:ASND) has risen 96.01% since August 24, 2016 and is uptrending. It has outperformed by 79.31% the S&P500.

Among 5 analysts covering Ascent Capital Group Inc (NASDAQ:ASCMA), 0 have Buy rating, 1 Sell and 4 Hold. Therefore 0 are positive. Ascent Capital Group Inc has $45 highest and $1400 lowest target. $15’s average target is 41.51% above currents $10.6 stock price. Ascent Capital Group Inc had 12 analyst reports since August 12, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, September 2 by Zacks. The company was downgraded on Wednesday, June 22 by Imperial Capital. On Friday, July 21 the stock rating was maintained by Stifel Nicolaus with “Hold”. The rating was maintained by Imperial Capital with “In-Line” on Thursday, August 11. The company was upgraded on Wednesday, November 9 by Imperial Capital. Imperial Capital maintained Ascent Capital Group Inc (NASDAQ:ASCMA) rating on Thursday, November 12. Imperial Capital has “Outperform” rating and $30 target. The stock of Ascent Capital Group Inc (NASDAQ:ASCMA) earned “Hold” rating by Piper Jaffray on Wednesday, August 9. The firm has “In-Line” rating given on Friday, August 11 by Imperial Capital. Imperial Capital maintained the shares of ASCMA in report on Thursday, May 11 with “Outperform” rating. The firm has “Hold” rating by BB&T Capital given on Thursday, June 16. See Ascent Capital Group Inc (NASDAQ:ASCMA) latest ratings:

11/08/2017 Broker: Imperial Capital Old Rating: Outperform New Rating: In-Line Old Target: $15 Downgrade
09/08/2017 Broker: Piper Jaffray Rating: Hold New Target: $14.0000 Maintain
21/07/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $16.0000 Maintain
11/05/2017 Broker: Imperial Capital Rating: Outperform Old Target: $21.00 New Target: $15.00 Maintain

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The company has market cap of $894.58 million. The Firm is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. It currently has negative earnings. The Firm is developing its product candidate, TransCon human growth hormone for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Among 3 analysts covering Ascendis Pharma (NASDAQ:ASND), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ascendis Pharma had 4 analyst reports since September 26, 2016 according to SRatingsIntel. The rating was maintained by Wedbush with “Outperform” on Friday, March 24. Wedbush initiated Ascendis Pharma A S (NASDAQ:ASND) rating on Monday, September 26. Wedbush has “Outperform” rating and $34 target.

Since March 17, 2017, it had 1 buying transaction, and 0 selling transactions for $4,800 activity. The insider FITZGERALD WILLIAM R bought 300 shares worth $4,800.

The stock decreased 2.93% or $0.32 during the last trading session, reaching $10.6. About shares traded. Ascent Capital Group Inc (NASDAQ:ASCMA) has declined 24.02% since August 24, 2016 and is downtrending. It has underperformed by 40.72% the S&P500.

Ascent Capital Group, Inc. is a holding company. The company has market cap of $136.52 million. The Company’s subsidiaries include Monitronics International, Inc. and LiveWatch Security, LLC (LiveWatch). It currently has negative earnings. The Company’s divisions include MONI, LiveWatch and Other Activities.

Investors sentiment increased to 1.25 in 2016 Q4. Its up 0.25, from 1 in 2016Q3. It increased, as 7 investors sold Ascent Capital Group Inc shares while 33 reduced holdings. 14 funds opened positions while 36 raised stakes. 9.80 million shares or 1.27% less from 9.93 million shares in 2016Q3 were reported. Hutchin Hill Capital Lp stated it has 0.01% in Ascent Capital Group Inc (NASDAQ:ASCMA). Moreover, Blackrock Institutional Na has 0% invested in Ascent Capital Group Inc (NASDAQ:ASCMA) for 313,316 shares. Royal Bank Of Canada holds 361 shares or 0% of its portfolio. Citigroup Inc has 17,631 shares. 7,978 were reported by Blackrock. 67 were accumulated by Da Davidson &. Alliancebernstein Limited Partnership has invested 0% in Ascent Capital Group Inc (NASDAQ:ASCMA). American Intl Gp accumulated 0% or 5,868 shares. Bogle Invest Mngmt Limited Partnership De stated it has 48,331 shares. Vnbtrust National Association invested in 38,173 shares or 0.34% of the stock. Blackrock Fund Advisors reported 338,443 shares. Next Fin Group Inc accumulated 0% or 5 shares. First Manhattan has invested 0% of its portfolio in Ascent Capital Group Inc (NASDAQ:ASCMA). Us Financial Bank De invested in 205 shares. Pnc Services Gp Incorporated reported 0% stake.